Stock DRTS ALPHA TAU MEDICAL LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Alpha Tau Medical Ltd.

Equities

DRTS

IL0011839383

Market Closed - Nasdaq
Other stock markets
 02:00:00 22/05/2024 am IST 		5-day change 1st Jan Change
2.71 USD 0.00% Intraday chart for Alpha Tau Medical Ltd. +2.89% -9.97%
06/05 Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow CI
07/03 Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
CI
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer
MT
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Alpha Tau Medical Ltd. Treats First Patient with Advanced Inoperable Pancreatic Cancer At Israel's Hadassah Medical Center
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Alpha Tau Medical Ltd. Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Alpha Tau Medical Ltd. Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
CI
Alpha Tau Medical Ltd. and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Alpha Tau Medical Ltd. Announces Alpha DaRT Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer Trial
CI
Alpha Tau Medical Granted Amended Radioactive License by Israeli Government
MT
Alpha Tau Medical Ltd. Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters
CI
Alpha Tau Medical Ltd. Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases
CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Alpha Tau Medical Ltd. Announces the Acceptance of Two Pre-Clinical Studies
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRTS Stock
  4. News Alpha Tau Medical Ltd.
  5. Highlights
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW